The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults [version 2; peer review: 2 approved]

The short-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide for the treatment of type 2 diabetes mellitus in Colombian adults [version 2; peer review: 2 approved]

Background Type 2 Diabetes Mellitus (T2DM) is a highly prevalent disease worldwide and in Colombia, representing one of the main causes of death and placing a considerable burden on healthcare systems. 13 classes of drugs are approved for the treatment of T2DM, with Glucagon-like Peptide-1 (GLP-1) r...

Full description

Bibliographic Details
Main Authors: Sharon Lechtig-Wassermann, Jhosep Blanco, Joshua Kock, Andrea-Marcela Suarez-Chacon, Yuli-V. Fuentes, Rosa Helena Bustos, Hans Liebisch-Rey
Format: Article
Language:English
Published: F1000 Research Ltd 2023-12-01
Series:F1000Research
Subjects:
Semaglutide
Dulaglutide
Pharmacoeconomic
Cost-effectiveness
eng
Online Access:https://f1000research.com/articles/12-914/v2

Internet

https://f1000research.com/articles/12-914/v2

Similar Items